]>
IRCT20190109042305N1 IRCT 2019-01-25 Mazandaran University of Medical Sciences nebulized Furosemide and spirometric indexes in Chronic Obstructive Pulmonary Disease exacerbation The effect of nebulized Furosemide in Chronic Obstructive Pulmonary Disease exacerbation patients. 2018-09-22 anticipated 47 Complete https://irct.ir/trial/37031 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method is Numbered drug containers. So that the drugs of each group are already in the boxes of the same shape, color, size and weight and are completely sealed and Encoding becomes A and B. Doctor prescribing medications and patients with prescription drugs (furosemide and placebo) are unaware. To collect data, a questionnaire was prepared and pre-coded according to A and B and randomly placed in a folder.The nurse will use the package of treatment for each patient based on the leaflet taken from this folder (randomly), Blinding description: The drugs of each group are already in the boxes of the same shape, color, size and weight and are completely sealed and Encoding becomes A and B. Doctor prescribing medications and patients with prescription drugs (furosemide and placebo) are unaware. To collect data, a questionnaire was prepared and pre-coded according to A and B and randomly placed in a folder.The nurse will use the package of treatment for each patient based on the leaflet taken from this folder (randomly). 3 Chronic obstructive pulmonary disease exacerbation. Intervention 1: Intervention group: The case group received 40 mg of furosemide (Chemidarou Industrial Company, Tehran, Iran, 20 mg/2 cc) in a 15-minute period. Intervention 2: Control group: The control group received 4 ml of normal saline serum of 0.9% as an nebulized in 15 minutes. Yes - There is a plan to make this available What will be shared: In this Study, all the Information on the main Outcome as well as the Side Effects are Shared When: The time to Start Accessing Data will be one Month after the Data is Printed To whom: The Data in this Study is Available to Researchers in Academic and Scientific Institutions as well as in Non-Related Fields. Conditions: The Data is Available after Printing and the Specified time Period and is used to Improve the Scientific Level Where to obtain: Dr Mir Saeid Ramezani .Email: mramezani@mazums.ac.ir How to obtain: This Data will be Available to the Applicant one Month after Printing Comments:
public Mir Saeid Ramezani
Imam khomeini Hospital, Amir Mazandarani street, Sari
sari Iran (Islamic Republic of) 4816633131 +98 11 3336 1700 mramezani@mazums.ac.ir Mazandaran University of Medical Sciences scientific Mir Saeid Ramezani
Imam khomeini Hospital, Amir Mazandarani street, Sari
sari Iran (Islamic Republic of) 4816633131 +98 11 3336 1700 mramezani@mazums.ac.ir Mazandaran University of Medical Sciences Iran (Islamic Republic of) COPD exacerbation patients FEV1/FVC less than 70% No need for ventilator 18 years no limit Both FEV1 Increase greater than 200 cc or 12% after salbutamol administration in spirometry The history of infectious diseases such as tuberculosis, recent respiratory infections, bronchiectasis and acute or chronic diarrhea Probability of malignancy based on examination Rheumatic arthritis, degenerative joint disease, vasculitis J44.1 Chronic obstructive pulmonary disease with (acute) exacerbation Treatment - Drugs Treatment - Drugs Intervention group: The case group received 40 mg of furosemide (Chemidarou Industrial Company, Tehran, Iran, 20 mg/2 cc) in a 15-minute period. Control group: The control group received 4 ml of normal saline serum of 0.9% as an nebulized in 15 minutes. Forced expiratory volume in 1 second (FEV1). Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry. Forced vital capacity. Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry. Peak Expiratory Flow Rate. Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry. Severity of respiratory distress. Timepoint: Before prescribing medications, as well as 30 minutes and one hour after administration. Method of measurement: Accessory muscle score. Adverse effect. Timepoint: Before prescribing medications, as well as 30 minutes and one hour after administration. Method of measurement: Patient evaluation. Sari University of Medical Sciences Approved 2018-06-26 Ethics committee of Mazandaran University of Medical Sciences Imam Khomeini Hospital Amir Mazandarani Street Sari Sari Mazandaran Iran (Islamic Republic of)